Exact Sciences
EXAS
#1543
Rank
โ‚น937.52 B
Marketcap
โ‚น5,066
Share price
5.86%
Change (1 day)
-14.69%
Change (1 year)
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.

P/E ratio for Exact Sciences (EXAS)

P/E ratio as of December 2024 (TTM): -37.3

According to Exact Sciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -37.2727. At the end of 2022 the company had a P/E ratio of -14.0.

P/E ratio history for Exact Sciences from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-14.0-37.82%
2021-22.5-6.62%
2020-24.1-81.51%
2019-130197.25%
2018-43.8-16.6%
2017-52.5548.88%
2016-8.1049.13%
2015-5.43-75.46%
2014-22.129.95%
2013-17.041.51%
2012-12.0-19.97%
2011-15.0-29.59%
2010-21.482.7%
2009-11.7638.29%
2008-1.58-78.36%
2007-7.3226.71%
2006-5.7843.73%
2005-4.02-23.41%
2004-5.25-22.23%
2003-6.750.92%
2002-6.69-5.52%
2001-7.08

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-4.32-88.42%๐Ÿ‡บ๐Ÿ‡ธ USA
16.4-144.11%๐Ÿ‡บ๐Ÿ‡ธ USA
-102 174.76%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0085-99.98%๐Ÿ‡บ๐Ÿ‡ธ USA
15.0-140.27%๐Ÿ‡ซ๐Ÿ‡ท France

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.